Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment Journal of Medicinal Chemistry Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine Cagrilintide peptides at Refresh Clinic Dubai: price, buy Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 ScienceDirect